Pu Tian Shi

Researchers are evaluating an artificial intelligence system to assist in classifying how deeply early esophageal squamous cell carcinoma invades tissue using endoscopic ultrasound. This helps provide a basis for preoperative T staging and supports diagnosis and treatment decisions. The study is a multicenter, prospective, randomized cohort trial, comparing AI-assisted grading to routine diagnosis methods in patients with early esophageal cancer or precancerous lesions. Participants will be randomly assigned to one of two groups the AI group, which uses artificial intelligence to assist in determining the invasion depth under endoscopic ultrasound, or the control group, which receives routine diagnosis without AI assistance. Each group is expected to include about 100 patients. The study uses central randomization with single masking, where the procedure is identified as protocol A or B by the operating physician based on allocation. During the study, researchers will assess the accuracy of grading the depth of cancer invasion over two years. They will also monitor secondary outcomes such as survival rate over three years and progression-free survival over one year. Participants undergo endoscopic ultrasound and pathological examinations, with detailed records reviewed. The study will last several years, ensuring thorough evaluation and follow-up to understand the impact of AI-assisted diagnosis on early esophageal cancer staging.

Researchers are evaluating the pain relief effects of wrist-ankle acupuncture in patients experiencing different types of pain after perianal surgery. This prospective clinical observation involves 60 patients aged 18 to 75 years who have postoperative pain with a Visual Analog Scale VAS score of 4 or higher. The study also aims to explore how postoperative pain influences the occurrence of urinary retention. Patients are divided into two groups based on their pain type sphincter spasm pain and acute incisional pain. All patients receive routine postoperative care including intravenous flurbiprofen infusion, herbal sitz baths, and pain education. Wrist-ankle acupuncture is given once daily when the pain score reaches 4 or higher, involving superficial needle insertion at specific zones on both lower limbs. Needles are kept in place for 0.5 to 1 hour, and treatment duration is adjusted based on symptom improvement. If pain remains high 30 minutes after acupuncture, additional analgesic medication is provided. During the study, researchers monitor pain scores before and after acupuncture, the frequency of pain medication use within three days post-surgery, and urinary retention scores 24 hours after surgery. Participants will be observed throughout their hospital stay to assess these outcomes and the overall effect of wrist-ankle acupuncture on postoperative pain and urinary retention.

Researchers are studying the role of HPV integration in predicting the prognosis of young women aged 45 and below diagnosed with cervical intraepithelial neoplasia grade 2 CIN2, a precancerous cervical condition. The study aims to explore the correlation between HPV integration, vaginal flora changes, and cervical cytology results to better understand disease progression and outcomes. This multi-center cohort study includes 300 participants from hospitals in China, focusing on the natural course of CIN2 without surgical or medication treatment when appropriate. Participants will be followed at enrollment and then at 3, 6, 9, and 12 months. At these visits, HPV viral integration tests, HPV genotyping tests, cervical cytology, and sequencing of vaginal secretions will be performed. Colposcopies and biopsies will be conducted at 6 and 12 months to closely monitor cervical tissue changes. The study observes participants under regular clinical follow-up without intervention unless disease progression occurs. During the study, participants will provide cervical secretions and exfoliated cell samples for testing. Researchers will assess cervical histopathology, HPV integration status, cervical cytology, vaginal flora diversity, and HPV genotyping at multiple time points. Outcomes measured include cervical tissue changes and HPV-related markers to evaluate the diseases natural course. The study lasts 12 months with scheduled clinical visits and laboratory assessments to monitor participants cervical health and HPV status throughout this period.

Researchers are evaluating the safety and effectiveness of neoadjuvant adebrelimab combined with chemotherapy in patients diagnosed with locally advanced esophageal squamous cell carcinoma ESCC. This exploratory, single-arm Phase 2 clinical study aims to understand how well this combination works before surgery in this patient group. The study is being conducted by The Affiliated Hospital of Putian University and focuses on patients with confirmed ESCC at specific clinical stages who have not yet received prior anti-tumor treatments. Participants will receive adebrelimab at a dose of 1200 mg or 20 mgkg through intravenous infusion every three weeks. They will also receive chemotherapy consisting of nanoparticle albumin-bound paclitaxel Nab-paclitaxel 100 mgm on days 1 and 8, and cisplatin 75 mgm on days 1, 2, and 3, both administered every three weeks. This neoadjuvant treatment is given before planned surgical resection, and patients are predicted to be eligible for R0 resection, which aims for complete tumor removal. During the study, participants will be closely monitored through various assessments including pathological complete response rate four weeks after surgery, surgical resection success, disease-free survival, overall survival, and response rates up to three months. Safety will be tracked by recording adverse events for up to two years. The total participation time includes neoadjuvant treatment, surgery, and follow-up assessments extending to 24 months to evaluate long-term outcomes and safety.

Researchers are investigating a new treatment approach for patients with HER2-positive muscle-invasive bladder cancer MIBC staged cT2-4aN0-1M0. This phase II, multicenter, open-label study evaluates combining zanidatamab and tislelizumab with chemotherapy before surgery, aiming to preserve the bladder selectively. The study focuses on assessing the treatments effectiveness and safety in this specific patient group. Participants receive neoadjuvant therapy consisting of zanidatamab, tislelizumab, and chemotherapy drugs such as cisplatin, gemcitabine, or nab-paclitaxel over four cycles, each lasting 21 days. After these initial treatments, patients are reassessed for clinical complete response cCR. Those achieving cCR continue maintenance therapy with zanidatamab and tislelizumab, while others may undergo radiotherapy or partial cystectomy followed by maintenance therapy or proceed directly to radical cystectomy with adjuvant tislelizumab. Throughout the trial, participants undergo regular evaluations including tumor assessments and safety monitoring. The main outcome is the rate of clinical complete response at the end of neoadjuvant therapy. Secondary outcomes include disease-free survival rates, recurrence-free survival, overall survival, safety, and quality of life measures over up to three years. The study aims to understand how well this treatment strategy can preserve the bladder and improve patient outcomes.

Researchers are evaluating normobaric hyperoxia NBO as a treatment for patients who have experienced an acute ischemic stroke and are transferred for endovascular thrombectomy EVT. The study aims to assess the effectiveness and safety of NBO in improving functional outcomes at 3 months after stroke. Stroke is a leading cause of death and disability, and although reperfusion treatments like thrombectomy improve blood flow, less than half of patients achieve favorable recovery. NBO is thought to protect the brain by rescuing hypoxic tissue and reducing damage processes, with advantages such as low cost and easy use. Participants will be randomly assigned to receive either NBO, which involves inhaling 100% oxygen alongside the best medical care, or best medical care alone. The study compares these two groups to see if NBO provides additional benefits. The treatment is given during the acute phase before or during transfer for EVT. The study includes a single-blind design and follows patients for outcomes over time. During the study, participants will have their disability level measured using the modified Rankin Scale at 90 days and one year after randomization. Other assessments include neurological function scores, imaging scans, infarct volume changes, and quality of life questionnaires at various time points. Safety and recovery progress are closely monitored throughout, with follow-up visits to track long-term effects. The total participation duration includes initial treatment and follow-up through one year.

Researchers are studying cervical neuroendocrine tumors by collecting clinical diagnosis and treatment data from 300 patients. This includes information like age, biopsy results, histopathology, and follow-up survival data. The goal is to analyze the molecular characteristics and prognosis of this cancer type to better understand its behavior and potential clinical applications. The study also gathers paraffin tissue samples from 100 cases across multiple centers to perform protein concentration and omics analyses. These tests help establish molecular features and identify prognostic markers of cervical neuroendocrine tumors. Participants medical and follow-up data are reviewed to assess outcomes such as mortality rate and disease-free survival within three years after surgery. The study builds a database to support ongoing research and analysis of cervical neuroendocrine tumors protein profiles and patient prognosis.

Researchers are studying cardiovascular diseases CVD including coronary heart disease, atrial fibrillation, and chronic heart failure in participants aged 40 years or older. The study aims to describe how common chronic obstructive pulmonary disease COPD is among these participants and to observe how combined heart and lung care affects their short-term health outcomes. Approximately 3,000 participants will be enrolled, with about 1,000 in each disease group. The study uses a behavioral intervention that includes guideline education and implementation at both the investigator and patient levels. Investigators receive disease education before enrollment, and cardiologists and pulmonologists provide ongoing disease education and coordinated treatment every four weeks. Participants will be followed up every four weeks to manage their care and monitor progress. Participants will undergo spirometry testing and complete questionnaires to assess their lung and heart health. Researchers will measure COPD prevalence, hospitalization rates, symptom scores, lung function, and other heart and lung-related biomarkers over 12 weeks. The study includes assessments of treatment adherence and changes in health status through repeated evaluations at baseline and weeks 4, 8, and 12. Safety and outcomes will be closely monitored throughout the study period.